PREFACE

The work typifies in this Ph.D. thesis represents “Studies on Pharmacokinetic drug Interactions in hepatic failure model”.

Chapter 1 Introduction described the overview of pharmacokinetic and pharmacodynamic drug interactions in liver failure/dysfunction model and the factors contribute for the drug interactions in liver failure.

The Chapter 2 Review of Literature provides detailed information on studies carried out in pharmacokinetic and pharmacodynamic drug-drug interactions between the repaglinide, ritonavir, atazanavir and indinavir in preclinical models.

The Chapter 3 Aims and objectives of the present study to determine the pharmacokinetic and pharmacodynamic drug-drug interactions in liver failure model.

In chapter 4 Material and Methods, the list of various materials that are used in the present investigation, procedure for the induction of diabetes mellitus, liver failure, estimation of repaglinide in plasma by LC-MS/MS method and software used for the calculation of pharmacokinetic parameters.

The chapter 5 Experimental results provide the details regarding the method development and validation of repaglinide in plasma by LC-MS/MS method, plasma concentration of repaglinide in different groups and pharmacokinetic and pharmacodynamic parameters in normal, diabetic and liver failure models.

Chapter 6 Discussion of Results section explains how the pharmacokinetic parameters like Cmax, Tmax, AUC_{0-t}, AUC_{t-∞}, t_{1/2}, clearance and pharmacodynamic parameters (glucose) change in normal, diabetic and hepatic impaired rats.

Chapter 7 Summary and Conclusion covers the present study along with various conclusions drawn from the study.

Reference lists out all the articles and books that are used as a source of support for the study carried out.